LH and FSH: The Pituitary Hormones That Govern Reproductive Health

LH and FSH: The Pituitary Hormones That Govern Reproductive Health

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are two glycoprotein hormones released by the anterior pituitary gland. Together, they form the control panel for reproductive function — directing the ovaries and testes to produce sex hormones, mature eggs, and generate sperm. Yet despite their central role, most people don't encounter an LH FSH blood test until something goes wrong: an irregular cycle, unexplained infertility, or a menopause transition that arrives earlier than expected.

That's a missed opportunity. LH and FSH are sensitive, early-signal biomarkers. Changes in their levels — particularly in the ratio between them — can surface years before a clinical diagnosis. This article breaks down what LH and FSH actually do, how to interpret your results across different life stages, and what evidence-based nutrition and supplementation strategies can support healthy gonadotropin signaling.

---

What LH and FSH Do: The Hypothalamic-Pituitary-Gonadal Axis

LH and FSH don't operate in isolation. They are part of the hypothalamic-pituitary-gonadal (HPG) axis — a three-tier signaling cascade that regulates nearly all reproductive hormone output.

1. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses.
2. GnRH stimulates the anterior pituitary to secrete LH and FSH into the bloodstream.
3. LH and FSH travel to the gonads (ovaries or testes), where they trigger sex hormone production and gametogenesis.

In women, FSH stimulates ovarian follicle growth and estrogen production during the follicular phase of the menstrual cycle. A mid-cycle LH surge — typically lasting 24–48 hours — triggers ovulation. After ovulation, LH supports the corpus luteum in producing progesterone.

In men, FSH is essential for spermatogenesis, acting on Sertoli cells in the testes. LH acts on Leydig cells to stimulate testosterone production. Both are required for normal male fertility (Bhasin et al., Journal of Clinical Endocrinology & Metabolism, 2018; doi.org/10.1210/jc.2018-00229).

When any tier of this axis is disrupted — by chronic stress, nutritional deficiency, thyroid dysfunction, or structural pituitary issues — LH and FSH levels shift detectably, often before symptoms fully emerge.

---

Pituitary Hormones and Fertility: What Your Numbers Should Look Like

Reference ranges for LH and FSH vary by sex, age, and — in women — menstrual cycle phase. A result that looks abnormal at first glance may be entirely appropriate depending on where in the cycle the blood was drawn. Timing matters enormously.

Women — Approximate Reference Ranges

Men — Approximate Reference Ranges

In men, LH below 1.7 IU/L may indicate secondary hypogonadism (pituitary or hypothalamic dysfunction), while elevated FSH — particularly above 12 IU/L — may suggest compromised spermatogenesis, since the pituitary compensates by producing more FSH when testicular feedback is insufficient (Krausz & Riera-Escamilla, Nature Reviews Urology, 2018; doi.org/10.1038/s41585-018-0003-3).

For women trying to conceive, day-2 or day-3 FSH is one of the most widely used ovarian reserve markers. FSH above 10 IU/L on cycle day 3 has been associated with reduced response to ovarian stimulation in IVF protocols, though it should always be interpreted alongside anti-Müllerian hormone (AMH) and antral follicle count (La Marca et al., Human Reproduction Update, 2010; doi.org/10.1093/humupd/dmq009).

If you're tracking hormonal biomarkers for fertility optimization, understanding which day to test LH and FSH is just as critical as understanding the numbers themselves.

---

LH FSH Ratio and PCOS: A Key Diagnostic Signal

One of the most clinically significant patterns in gonadotropin testing is an elevated LH-to-FSH ratio, and it sits at the center of polycystic ovary syndrome (PCOS) evaluation.

In healthy women during the early follicular phase, the LH:FSH ratio is roughly 1:1. In women with PCOS, LH secretion is often increased in both frequency and amplitude, while FSH remains relatively suppressed. This drives the LH:FSH ratio above 2:1 or even 3:1 in a significant proportion of PCOS cases.

A landmark study by Balen et al. (Human Reproduction, 1995; PMID: 7835384) found that elevated LH — particularly an LH:FSH ratio greater than 2 — was associated with impaired ovulation, reduced fertilization rates, and higher miscarriage risk in women with PCOS. More recent meta-analyses have confirmed that women with PCOS exhibit significantly higher LH pulse frequency and amplitude compared to eumenorrheic controls (Eagleson et al., Journal of Clinical Endocrinology & Metabolism, 2000; PMID: 10720052).

The mechanism behind this ratio distortion is central: insulin resistance — present in 50–70% of women with PCOS — amplifies GnRH pulse frequency at the hypothalamus, which preferentially stimulates LH over FSH (Dunaif, Endocrine Reviews, 1997; PMID: 9241508).

This is why the LH FSH blood test is not a standalone diagnostic for PCOS but a critical piece of a broader hormonal picture that includes fasting insulin, testosterone, SHBG, and AMH. Understanding the connection between insulin resistance and PCOS hormonal patterns can help contextualize what your ratio means.

What an Elevated LH:FSH Ratio May Indicate

• PCOS (most common cause in reproductive-age women)
• Hypothalamic dysfunction from excessive exercise or low body weight
• Stress-driven GnRH dysregulation
• Early ovarian failure (when both LH and FSH rise together)

---

FSH as a Menopause Marker: Timing and Thresholds

FSH is the most sensitive early indicator of declining ovarian reserve and the approach of menopause. As the ovaries produce less estrogen and inhibin B — two key negative feedback signals to the pituitary — FSH rises progressively in an attempt to stimulate follicle development that the aging ovary can no longer sustain.

The Stages of Reproductive Aging Workshop (STRAW+10) framework, updated in 2012, defines the menopausal transition based in part on FSH thresholds. Specifically, an FSH consistently above 25 IU/L (measured on cycle days 2–5) in the context of menstrual irregularity is a recognized marker of the late menopausal transition (Harlow et al., Menopause, 2012; doi.org/10.1097/gme.0b013e318245d8f7).

Postmenopause, FSH typically rises above 40 IU/L and may reach 100–150 IU/L or higher. LH also rises substantially post-menopause, though generally to a lesser degree than FSH.

Key clinical nuances:

• A single elevated FSH reading is insufficient for a menopause diagnosis — testing should be repeated after 4–6 weeks, since FSH fluctuates significantly during the perimenopause transition.
• Exogenous estrogen (including some supplements with phytoestrogenic activity) can suppress FSH artificially, potentially masking true ovarian status.
• In women under 40, FSH above 25 IU/L on two separate cycle-day-3 measurements warrants evaluation for premature ovarian insufficiency (POI), a condition affecting approximately 1 in 100 women (Nelson, New England Journal of Medicine, 2009; PMID: 19692690).

Tracking FSH longitudinally — rather than as a single snapshot — is far more informative. Platforms that integrate lab data over time, like Ones, can identify trends in FSH trajectory that a single test would miss entirely.

---

Gonadotropin Testing: When to Test and What to Test Alongside It

An LH FSH blood test provides the most value when ordered as part of a comprehensive hormonal panel. Testing LH and FSH in isolation, without context from related markers, limits clinical interpretation significantly.

Recommended Panel by Indication

Timing guidance for women:

• Day 2–3 of cycle: Best for ovarian reserve assessment (FSH, estradiol, AMH)
• Day 21 (or 7 days post-ovulation): Best for luteal progesterone confirmation
• LH surge testing: Serial testing around cycle day 10–14 for ovulation prediction

Prolactin should almost always accompany gonadotropin testing. Hyperprolactinemia suppresses GnRH pulsatility, causing secondary suppression of LH and FSH — a pattern that can mimic hypothalamic dysfunction without the same underlying cause (Melmed et al., Journal of Clinical Endocrinology & Metabolism, 2011; doi.org/10.1210/jc.2010-1692).

For men concerned about low testosterone and its relationship to LH signaling, pairing gonadotropin results with total and free testosterone is essential to distinguish primary from secondary hypogonadism — a distinction that completely changes the treatment approach.

---

What Drives LH and FSH Out of Range?

Beyond structural pathology (pituitary adenoma, premature ovarian insufficiency), several modifiable lifestyle and nutritional factors influence gonadotropin output.

Factors that suppress LH and FSH:

• Hypothalamic amenorrhea from energy deficit or excessive exercise — GnRH pulse frequency drops, suppressing both hormones (Loucks et al., Journal of Clinical Endocrinology & Metabolism, 1998; PMID: 9626108)
• Chronic psychological stress — elevated cortisol inhibits GnRH at the hypothalamus
• Obesity and hyperinsulinemia — excess insulin amplifies androgen production and disrupts HPG axis feedback
• Hyperprolactinemia — from pituitary adenoma, dopamine-disrupting medications, or chronic nipple stimulation
• Thyroid dysfunction — both hypothyroidism and hyperthyroidism alter sex hormone binding and gonadotropin secretion (Poppe et al., European Journal of Endocrinology, 2008; doi.org/10.1530/EJE-07-0648)

Factors that elevate LH and FSH:

• Ovarian aging and menopause transition
• Primary hypogonadism (gonadal failure — testes or ovaries not responding to LH/FSH signal)
• Turner syndrome, Klinefelter syndrome
• Gonadotoxic exposures (chemotherapy, radiation)

---

How Ones Addresses This: Targeted Support for HPG Axis Function

While no supplement corrects structural pituitary or gonadal pathology, several clinically dosed ingredients have demonstrated meaningful effects on the hormonal cascades that LH and FSH regulate. Ones builds custom formulas based on individual lab results — including gonadotropin panels — and sources ingredients at doses that match clinical evidence.

Ashwagandha (KSM-66, 600mg): A double-blind, randomized controlled trial in 57 infertile men found that KSM-66 ashwagandha at 675mg/day for 90 days significantly improved LH levels, testosterone, and semen parameters compared to placebo (Ambiye et al., Evidence-Based Complementary and Alternative Medicine, 2013; doi.org/10.1155/2013/571420). Ones uses the same KSM-66 extract at 600mg — the minimum dose used in clinical stress and hormonal research. You can read more about the clinical evidence for ashwagandha on cortisol and hormonal health and how it interacts with the HPG axis.

Vitamin D3 + K2 (MK-7): Vitamin D receptors are expressed in the pituitary, ovary, and testes. A systematic review found significant associations between vitamin D deficiency and both reduced FSH receptor expression and impaired folliculogenesis (Lerchbaum & Obermayer-Pietsch, European Journal of Endocrinology, 2012; doi.org/10.1530/EJE-11-1050). Ones pairs D3 with MK-7 to support calcium utilization and avoid arterial calcification at higher D3 doses — a combination discussed in detail in the vitamin D3 and K2 synergy guide.

Magnesium Glycinate: Magnesium deficiency is disproportionately common in women with PCOS and correlates with worsened insulin resistance — a key driver of LH:FSH ratio distortion. A 2017 randomized trial found that magnesium supplementation reduced fasting insulin and improved hormonal markers in women with PCOS (Razavi et al., Biological Trace Element Research, 2022; doi.org/10.1007/s12011-021-02900-x). Ones includes magnesium glycinate in its Magnesium Complex blend for superior absorption over magnesium oxide or citrate.

Ones' AI health practitioner cross-references blood work — including LH, FSH, estradiol, and insulin — against your wearable data and health history to determine which of its 70+ clinical-grade ingredients belong in your formula, at what dose, and in which of its 6, 9, or 12-capsule daily plans. That's a fundamentally different approach from choosing a prenatal or hormonal support supplement off a shelf.

---

Key Takeaways

• LH and FSH are early-signal biomarkers. Changes in these pituitary hormones often precede clinical diagnoses of PCOS, premature ovarian insufficiency, or hypogonadism — making proactive testing worthwhile.
• The LH:FSH ratio matters as much as individual values. A ratio consistently above 2:1 on early follicular phase testing is a recognized PCOS signal and should prompt evaluation for insulin resistance alongside standard PCOS markers.
• FSH is the most sensitive menopause indicator. A rising day-2/3 FSH — even with regular cycles — signals declining ovarian reserve; consistently above 25 IU/L with menstrual irregularity indicates late menopausal transition.
• Timing your test is non-negotiable for women. LH and FSH fluctuate enormously across the menstrual cycle; day-2 or day-3 testing (for ovarian reserve) and mid-cycle testing (for ovulation confirmation) serve different clinical purposes.
• Modifiable factors drive many gonadotropin imbalances. Chronic stress, energy deficit, insulin resistance, thyroid dysfunction, and vitamin D deficiency all influence HPG axis output — and can be addressed through targeted nutrition and supplementation.
• Clinically dosed ingredients — KSM-66 ashwagandha, Vitamin D3 + K2, and Magnesium Glycinate — have meaningful evidence for supporting the hormonal cascades that LH and FSH regulate, particularly when selected based on your individual lab results rather than generic protocols.

---

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment of any hormonal or reproductive health condition.